These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 12201674

  • 21. The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
    Lunt SJ, Cawthorne C, Ali M, Telfer BA, Babur M, Smigova A, Julyan PJ, Price PM, Stratford IJ, Bloomer WD, Papadopoulou MV, Williams KJ.
    Br J Cancer; 2010 Jul 13; 103(2):201-8. PubMed ID: 20588272
    [Abstract] [Full Text] [Related]

  • 22. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
    Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh JA, Papadopoulou M, Bloomer WD, Goldenberg DM.
    Int J Cancer; 2001 Nov 13; 94(4):564-71. PubMed ID: 11745445
    [Abstract] [Full Text] [Related]

  • 23. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
    Masunaga S, Ono K, Nishimura Y, Kanamori S, Saga T, Suzuki M, Kinashi Y, Takagaki M, Kasai S, Nagasawa H, Uto Y, Hori H.
    Int J Radiat Oncol Biol Phys; 2000 Jun 01; 47(3):799-807. PubMed ID: 10837967
    [Abstract] [Full Text] [Related]

  • 24. Enhancement of cisplatin sensitivity of quiescent cells in solid tumors by combined treatment with tirapazamine and low-temperature hyperthermia.
    Masunaga S, Ono K, Hori H, Akaboshi M, Kawai K, Suzuki M, Kinashi Y, Kasai S, Nagasawa H, Uto Y.
    Radiat Med; 1998 Jun 01; 16(6):441-8. PubMed ID: 9929144
    [Abstract] [Full Text] [Related]

  • 25. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
    Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, Brown JM.
    Neoplasia; 1999 Nov 01; 1(5):461-7. PubMed ID: 10933062
    [Abstract] [Full Text] [Related]

  • 26. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M.
    Jpn J Cancer Res; 1996 Jan 01; 87(1):98-104. PubMed ID: 8609056
    [Abstract] [Full Text] [Related]

  • 27. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 28. NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
    Papadopoulou MV, Bloomer WD, Hollingshead MG.
    Anticancer Res; 2005 Jan 15; 25(3B):1865-9. PubMed ID: 16158918
    [Abstract] [Full Text] [Related]

  • 29. Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.
    Papadopoulou MV, Bloomer WD, Taylor AP, Hernandez M, Blumenthal RD, Hollingshead MG.
    Radiat Res; 2007 Jul 15; 168(1):65-71. PubMed ID: 17722994
    [Abstract] [Full Text] [Related]

  • 30. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ, Menke D, Brown JM.
    Int J Radiat Oncol Biol Phys; 1994 Jan 01; 28(1):145-50. PubMed ID: 8270435
    [Abstract] [Full Text] [Related]

  • 31. Radiosensitization effect by combination with paclitaxel in vivo, including the effect on intratumor quiescent cells.
    Masunaga SI, Ono K, Suzuki M, Nishimura Y, Kinashi Y, Takagaki M, Hori H, Nagasawa H, Uto Y, Tsuchiya I, Sadahiro S, Murayama C.
    Int J Radiat Oncol Biol Phys; 2001 Jul 15; 50(4):1063-72. PubMed ID: 11429234
    [Abstract] [Full Text] [Related]

  • 32. Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors.
    Maxim PG, Carson JJ, Ning S, Knox SJ, Boyer AL, Hsu CP, Benaron DA, Walleczek J.
    Radiat Res; 2004 Aug 15; 162(2):185-93. PubMed ID: 15387146
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy.
    Jounaidi Y, Waxman DJ.
    Cancer Res; 2000 Jul 15; 60(14):3761-9. PubMed ID: 10919648
    [Abstract] [Full Text] [Related]

  • 35. Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine.
    Wouters BG, Delahoussaye YM, Evans JW, Birrell GW, Dorie MJ, Wang J, MacDermed D, Chiu RK, Brown JM.
    Cancer Res; 2001 Jan 01; 61(1):145-52. PubMed ID: 11196153
    [Abstract] [Full Text] [Related]

  • 36. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
    Hicks KO, Siim BG, Pruijn FB, Wilson WR.
    Radiat Res; 2004 Jun 01; 161(6):656-66. PubMed ID: 15161354
    [Abstract] [Full Text] [Related]

  • 37. Single-dose pharmacokinetics of the DNA-binding bioreductive agent NLCQ-1 (NSC 709257) in CD2F1 mice.
    Reid JM, Squillace DP, Ames MM.
    Cancer Chemother Pharmacol; 2003 Jun 01; 51(6):483-7. PubMed ID: 12715203
    [Abstract] [Full Text] [Related]

  • 38. Changes in the sensitivity of intratumor cells during fractionated tirapazamine administration.
    Masunaga S, Ono K, Suzuki M, Kinashi Y, Takagaki M, Kasai S, Nagasawa H, Uto Y, Hori H.
    Jpn J Cancer Res; 2000 Jul 01; 91(7):731-6. PubMed ID: 10920281
    [Abstract] [Full Text] [Related]

  • 39. Applicability of combination with tirapazamine in boron neutron capture therapy.
    Masunaga S, Ono K, Sakurai Y, Hori H, Kobayashi T, Takagaki M, Suzuki M, Kinashi Y, Akaboshi M.
    Jpn J Cancer Res; 1998 Jul 01; 89(7):768-74. PubMed ID: 9738984
    [Abstract] [Full Text] [Related]

  • 40. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine.
    Hay MP, Gamage SA, Kovacs MS, Pruijn FB, Anderson RF, Patterson AV, Wilson WR, Brown JM, Denny WA.
    J Med Chem; 2003 Jan 02; 46(1):169-82. PubMed ID: 12502371
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.